Navigation Links
ICBS acquires 30% interest in Bacteria Bank Ltd.
Date:10/30/2007

NEW YORK and MONTREAL, Oct. 30 /PRNewswire-FirstCall/ - ICBS Limited (PINKSHEETS: ICBM), today announced the acquisition of 30% interest in Bacteria Bank Ltd.

Bacteria Bank Ltd., is a Bio medical company that owns over ten thousand cryogenically stored bacteria for use in medical research, located in Montreal Canada. The company is headed by Dr. Karl Weiss a world renowned bacteriologist.

Dr. Karl Weiss is a Microbiologist and Infectious Diseases Specialist at Maisonneuve-Rosemont Hospital in Montreal . He is also Associate Clinical Professor at the Faculty of Medicine at University of Montreal , and the director of pharmacological research at Maisonneuve-Rosemont hospital. He is also an associate member of the division of infectious diseases at the Jewish General Hospital in Montreal , and an adjunct-professor of Medicine at McGill University.

Bacteria bank has a unique collection of over 10,000 frozen bacteria which can be used for many different purposes.

1. susceptibility testing of potentially promising anti-microbial

agents developed by biotech companies or researchers in

universities.

2. susceptibility testing of new antibiotics against specific and

emerging pathogens such as MRSA ( Methicillin resistant

Staphyloccocus aureus), VRE ( Vancomycin Resistant Enterococcus).

3. susceptibility testing against a wide array of Gram negative

agents ( E. coli, Salmonella, shigella, and other gastro-

intestinal pathogens responsible for million of deaths every year

in the world)

4. susceptibility testing of new agents against Streptococcus

pneumoniae responsible for the majority of sinusitis, otitis

media, pneumonia and some forms of bronchitis. In North America

only, there are over 300 million of antibiotic prescriptions in

the outpatients setting, and S.pneumonie is the number one target

overall by far.

5. bacteria useful for the development of newly designed genetically

derived products ( human and animal hormones, growth factors,

cytokines...)

6. bacteria useful for teaching purposes ( Pharmaceutical companies,

universities and medical schools)

Speaking from the corporate head office in Montreal, Garth McIntosh, President &CEO of ICBS said, " This acquisition will further strengthen our position in the Bio medical industry". ICBS also owns 100% of Canadian Bio Med Systems Ltd. McIntosh further stated " I want to thank all of our shareholders that have supported us in the past year, we are working very hard to make this a profitable year for all. Thank you all for your encouragement and support".

You can visit them at: http://www.bacteriabank.com

This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a result of any number of factors, including the risk factors contained in the Company's disclosure documents.


'/>"/>
SOURCE INTER CANADIAN BUSINESS SERVICE
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Fiserv acquires crime management software firm
2. GenTel acquires GlaxoSmithKline chip platform
3. Tushaus Computer acquires managed service business
4. RedPrairie acquires Denver software company
5. Eagle Technology acquires some synergy
6. Brady Corp. acquires Korean counterpart
7. Canadian firm acquires Silicon Logic
8. Imago acquires synergistic British firm
9. Fiserv acquires insurance, training product lines
10. Amazon acquires Madison-based Shopbop
11. Metavante acquires health-care payments firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ComplianceOnline, the leading governance, risk ... its 3rd Annual Medical Device Summit 2017 venue and speaker lineup. The Summit will ... in Boston, MA. , The Omni Parker House Hotel, which is located at 60 ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, ... oncology and drug-delivery therapies, today announced that an ... and Drug Administration voted 11 to 0 that ... skin) injection was favorable for patients in the ... lymphoma and chronic lymphocytic leukemia. The FDA action ...
(Date:3/29/2017)... ... March 29, 2017 , ... ACEA Biosciences, a privately owned ... travel award to noteworthy scientists who will be presenting research using ACEA Biosciences’ ... of awards are being given to two postdoctoral fellows studying pathogen capture by ...
(Date:3/29/2017)... ... March 29, 2017 , ... Bactana Animal Health, a company developing natural products ... through enhancement of the gut microbiota, today announced the closing of its first round ... York-based Sustainable Income Capital Management, LLC and a number of private investors. The company ...
Breaking Biology Technology:
(Date:3/7/2017)... 2017 Brandwatch , the leading social intelligence company, ... Trust to uncover insights to support its reporting, help direct ... The UK,s leading youth charity will be using Brandwatch Analytics social ... a better understanding of the topics and issues that are a ... ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
Breaking Biology News(10 mins):